Optimisation of [11C]Raclopride production using a Synthra GPextent system
Gary Perkins, Rajeev Sheth, Ivan Greguric
1Australian Nuclear Science and Technology Organisation Camperdown, P.O. Box M34 Camperdown, Australia 2050. gary.perkins@ansto.gov.au.
Current Radiopharmaceuticals
|October 23, 2014
Summary
Optimized production of the dopamine D2 receptor radiotracer, [(11)C]Raclopride, achieved a 4% yield in 25 minutes. This advancement enhances clinical and preclinical imaging capabilities with high radiochemical purity and specific activity.
Area of Science:
- Radiochemistry
- Nuclear Medicine
- Neuroscience
Background:
- [(11)C]Raclopride is a vital radiotracer for dopamine D2 receptor imaging in clinical and preclinical settings.
- Existing production methods for [(11)C]Raclopride vary, utilizing traditional vessel reactions, cartridges, or captive solvents.
Purpose of the Study:
- To optimize the automated synthesis of [(11)C]Raclopride using a Synthra GPextent synthesizer.
- To compare different production methods for [(11)C]Raclopride and identify optimal conditions.
Main Methods:
- Utilized a Synthra GPextent automated synthesizer for [(11)C]Raclopride production.
- Investigated and optimized various synthesis parameters to maximize yield and purity.
- Evaluated production using 100 GBq of [(11)C]CO2 as precursor.
Main Results:
- Achieved a reproducible radiochemical yield of 4±2% (non-decay corrected) of [(11)C]Raclopride.
- Synthesis time was optimized to 25 minutes per batch.
- Obtained high radiochemical purity (>95%) and specific activities of 135±41 MBq/nmol at the end of synthesis.
Conclusions:
- The optimized automated synthesis provides an efficient method for producing [(11)C]Raclopride.
- This improved production method supports reliable and high-quality radiotracer availability for PET imaging.
- The results demonstrate the capability of the Synthra GPextent for routine production of this important neuroimaging agent.
Related Concept Videos
01:30Production of Pharmaceuticals
88
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
88
01:27Upstream Processing
95
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
95